Abstract：
Immune checkpoint inhibitors (ICI) have revolutionized the landscape of cancer treatment. Although several studies have shown that ICIs have a better safety profile than chemotherapy, some patients develop immune-related adverse events (irAEs), which require specialized and multidisciplinary management. Since ICI indications are rapidly increasing, it is crucial that clinicians involved in cancer care learn to identify irAEs and manage them properly. Here, we report a case series of 23 patients with severe irAEs requiring hospitalization over a period of 12 months and seize the opportunity to review and update different general features related to irAEs along with the management of the most frequent severe irAEs in our series.
摘要：
免疫检查点抑制剂（ICI）彻底改变了癌症治疗的前景。尽管一些研究表明ICIs比化疗具有更好的安全性，一些患者出现免疫相关不良事件(irAE)，这需要专业化和多学科的管理。由于ICI适应症正在迅速增加，至关重要的是,参与癌症治疗的临床医生要学会识别和正确管理.这里,我们报告了一个病例系列,包括23例需要在12个月内住院治疗的严重irAE患者,并抓住机会回顾和更新与irAE相关的不同一般特征,以及我们系列中最常见的严重irAE的管理.
